Phosphatidylcholine (PC) is the predominant phospholipid in mammalian membranes, representing 40-50% of total phospholipid content and serving as the only proven essential phospholipid for very-low-density lipoprotein (VLDL) assembly and triglyceride export.

Beyond its role as a bioavailable choline donor, PC contributes to membrane architecture, neurotransmitter acetylcholine synthesis, and methylation metabolism.

Clinical and nutritional evidence consistently highlights global inadequacy of choline intake, with fewer than 10% of women and pregnant individuals meeting Adequate Intake (AI) levels.

PC supplementation is uniquely positioned to address this gap with superior bioavailability, lower TMAO formation risk compared to free choline salts, and additional lipid-stabilizing functions.

PC supports hepatic health by reversing fatty liver and reducing elevated liver enzymes through VLDL-mediated lipid clearance.

It enhances neurological function by stabilizing neuronal membranes, supporting acetylcholine synthesis, and synergizing with DHA to preserve synaptic signaling and cognitive performance.

In the cardiovascular system, PC integrates into lipoproteins and vascular membranes, facilitating reverse cholesterol transport, regulating endothelial function, and attenuating inflammatory signaling (e.g., NF-κB, IL-6, TNF-α).

During pregnancy, PC provides sustained choline delivery essential for fetal neurodevelopment, DNA methylation, and maternal hepatic resilience.

Particularly suitable populations include individuals with NAFLD or metabolic dysfunction, cognitive decline, pregnancy and lactation demands, vegetarians and vegans with low dietary choline, and those at cardiovascular risk.

As a structural lipid and functional nutrient, PC represents an integrative solution to the triple gap of modern diets: choline deficiency, phospholipid insufficiency, and low omega-3 intake.